Alpha adrenergic receptor agonists for treatment of inflammatory diseases
A preparation and inflammation technology, applied in the field of α-adrenergic receptor agonists for the treatment of inflammatory diseases, can solve the problems that α-adrenergic receptor agonists are not widely recognized as effective treatments
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0280] Embodiment 1: preparation test
[0281] The inventors prepared a number of formulations of clonidine in which they varied polymer type, drug loading, excipients (including some formulations where no excipients were present), pellet size, and processing. These formulations are described in Table 1, Table 2 and Table 3 below. Multiple assays were performed on these formulations, including in vitro release assays measuring the microgram quantities released and the cumulative percent release of clonidine. The results of these experiments are presented in Figure 7-3 6 in.
[0282] In vitro efflux studies were performed in phosphate buffered saline (PBS, pH 7.4) at 37°C. Briefly, sticks (n=3) were weighed before immersion in 5 mL of PBS. At regular intervals, PBS was removed for analysis and replaced with 5 mL of fresh PBS. The PBS-run-out buffer was analyzed for clonidine content using a UV-Vis spectrophotometer.
[0283] Table 1
[0284] Table 2
[0285] ...
Embodiment 2
[0291] In the Chronic Constriction Injury Model in rats, the inventors evaluated the efficacy of a 5-month clonidine / polymer depot formulation. The animal model is the Bennett model (Wistar rat). Objective: To determine whether a 5-month polymeric clonidine efflux long-acting formulation can improve pain-related behavioral responses in a rat model of neuropathic pain.
[0292] Experimental Design: Four loose chromic bowel bandages, 1 mm apart, were tied around the common sciatic nerve at the mid-thigh. Each animal received either the test treatment or the control article treatment - dosing as described in Table 5.
[0293] Group No deal with dose comment 1 Clonidine 0.02mg / kg SC clonidine control 2 100DL 7E 0% 4 pellets (3mm×0.7mm) 3 100DL 7E 5% Clonidine HCl; 4 pills (3 mm×0.7mm) 4 100DL 5E 5% 3 pills (3mm×0.7mm) 5 100DL 5E 7% 3 pills (3mm×0.7mm) 6 100DL 7E 7% 3 pills (3mm××0.7mm) ...
PUM
Property | Measurement | Unit |
---|---|---|
diameter | aaaaa | aaaaa |
length | aaaaa | aaaaa |
length | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com